Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146022 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
A Phase 3 study of Androgenetic Alopecia and Hair Loss, sponsored by Veradermics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 552
- Enrollment target
- 20
- Study locations
NCT07146022 is a Phase 3 study of Androgenetic Alopecia and Hair Loss that is actively recruiting participants, run by Veradermics. The registered enrollment target is 552 participants, above the 130-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (325% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT07146022, a Phase 3 study of Androgenetic Alopecia and Hair Loss, is actively recruiting participants, sponsored by Veradermics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 552 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VDPHL01 QD
- DRUG VDPHL01 BID
Study Locations (20)
California
- Site 69 - Encino
- Site 2 - Fremont
- Site 64 - Manhattan Beach
- Site 93 - Northridge
- Site 66 - Santa Monica
- Site 34 - Sherman Oaks
- Site 94 - Thousand Oaks
- Site 21 - Vista
Florida
- Site 17 - Aventura
- Site 71 - Boca Raton
- Site 86 - Coral Gables
- Site 62 - Coral Gables
- Site 99 - Miami
- Site 54 - Ocala
Alabama
- Site 73 - Birmingham
- Site 89 - Birmingham
Colorado
- Site 5 - Castle Rock
- Site 24 - Greenwood Village
Arizona
- Site 77 - Phoenix
Arkansas
- Site 30 - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07146022
The ClinicalTrials.gov registry entry for NCT07146022 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 552 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 130-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (325% higher). The listed sponsor is Veradermics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Androgenetic Alopecia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07146022 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT07146022 about?
NCT07146022 is a clinical study titled "Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)". This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA. T...
What is the current status of trial NCT07146022?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 552 participants. The study started on 2025-07-25. Estimated completion is 2028-01.
What conditions does trial NCT07146022 study?
This clinical trial studies the following conditions: Androgenetic Alopecia, Hair Loss, AGA, Androgenetic Alopecia (AGA), Female Androgenetic Alopecia.
What interventions are being tested in trial NCT07146022?
The interventions under investigation include: Placebo (DRUG), VDPHL01 QD (DRUG), VDPHL01 BID (DRUG).
Who is sponsoring clinical trial NCT07146022?
This trial is sponsored by Veradermics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07146022 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
COMPLETED · Phase 3
-
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
RECRUITING · NA
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.